Phase I study of high dose etoposide phosphatase with filgrastim (G-CSF) in the treatment of advanced refractory malignancies

Investigational New Drugs

Volumn 15, Issue 4, 1997, Pages 325-329

  Hainsworth, John D ^a,b   Utley, Susan M ^a   Greco, F Anthony ^a  

^a CENTENNIAL MEDICAL CENTER   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Etoposide phosphate

Indexed keywords

ANTINEOPLASTIC ALKALOID; ETOPOFOS; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG TOLERABILITY; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE MARROW DISEASES; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; FILGRASTIM; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASMS; ORGANOPHOSPHORUS COMPOUNDS; PLATELET COUNT;

EID: 0031424629     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005954022984     Document Type: Article

References (19)

1. Williams SD, Birch R, Einhorn LH: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
2. Hainsworth JD, Williams SD, Einhorn LH: Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin. Results of a South-western Cancer Study Group trial. J Clin Oncol 3:666-671, 1985
3. Evans WK, Shepherd FA, Feld R: VP-16 and cisplatin as first-line therapy of small cell lung cancer. J Clin Oncol 3:1471-1477, 1995
4. Rodriguez MA, Cabanillas FC, Velaquez W: Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 13:1734-1741, 1995
5. Bennett JM, Lyman GH, Cassileth PA: A Phase II trial of VP16-213 in adults with refractory acute myeloid leukemia: An Eastern Cooperative Oncology Group study. Am J Clin Oncol 7:471-473, 1984
6. Wolff SN, Fer MF, McKay CM: High-dose VP16-213 and autologous bone marrow transplantation for refractory malignancies - a Phase I study. J Clin Oncol 1:701-715, 1983
7. Verdonck CF, Dekker AW, Vendirk PJ: Intensive cytoreductive therapy followed by autologous bone marrow transplantation for patients with hematologic malignancies or solid tumors. Cancer 60:289-295, 1987
8. Philip T, Guglielmi C, Hagenbeck A: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
9. Margolin K, Doroshow JH, Ahn C: Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol 14:2631-2637, 1996
10. Rose WK, Basler GA, Trail PA: Preclinical antitumor activity of a soluble etoposide analog, BMY-40481. Invest New Drugs 8:525-532, 1990
11. Thompson DS, Greco FA, Miller AA: A Phase I study of etoposide phosphate administered as a daily 30 minute infusion for 5 days. Clin Pharmacol Ther 57:499-507, 1995
12. Budman DR, Iqwemezie LN, Kaul S: Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors. J Clin Oncol 12:1902-1909, 1994
13. Hainsworth JD, Levitan N, Wampler GZ: A Phase II randomized study of cisplatin plus etoposide phosphate of etoposide in the treatment of small cell lung cancer. J Clin Oncol 13:1436-1442, 1995
14. Kreis W, Budman DR, Vinciquerra V: Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors. Cancer Chemother Pharmacol 38:378-384, 1996
15. Wolff SN, Johnson DH, Hande KR: High dose VP16-213 as single agent chemotherapy for small cell carcinoma of the lung. Cancer Treat Rep 67:957-958, 1983
16. Brown RA, Herzig RH, Wolff SN: High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 76:473-479, 1990
17. Postmus PE, Mulder NH, Sleijfer DT: High-dose etoposide for refractory malignancies: A Phase I study. Cancer Treat Rep 68:1471-1474, 1984
18. Slevin ML, Clark PL, Osborne RJ: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 7:1330-1340, 1990
19. Fields SZ, Budman DR, Young RR: Phase I study of high-dose etoposide phosphate in man. Bone Marrow Transplant 18:851-856, 1996